| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Instituto de Investigaciones Materno Infantil, IDIMI y Departamento de Obstetricia y Ginecología (L.D., P.K., R.R.G., O.C., M.V.), and Departamento de Patología (I.R.), Facultad de Medicina, Universidad de Chile; Hospital Clínico San Borja Arriarán, 6519100 Santiago, Chile; Facultad de Ciencias Biológicas, Pontificia Universidad Católica (P.C.), Santiago, Chile; and Center for Research on Reproduction and Womens Health, University of Pennsylvania (L.K.C., J.F.S.), Philadelphia, Pennsylvania 19104
Address all correspondence and requests for reprints to: Dr. Luigi Devoto, Instituto de Investigaciones Materno-Infantil, Departamento de Obstetricia y Ginecología, Facultad de Medicina, Universidad de Chile, P.O. Box 226-3, 6519100 Santiago, Chile. E-mail: ldevoto{at}machi.med.uchile.cl
Abstract
The expression of the steroidogenic acute regulatory protein (StAR) in the human corpus luteum (CL) was examined throughout the luteal phase. The primary 1.6-kb StAR transcript was in greater abundance in early (3.1-fold) and mid (2.2-fold) luteal phase CL compared with late luteal phase CL. The larger StAR transcript (4.4 kb) was found in early and midluteal phase CL, but was not detected in late luteal phase specimens. Mature StAR protein (30 kDa) was present in lower amounts within late CL compared with early and midluteal phase CL. The StAR preprotein (37 kDa) was also detected in greater abundance in early and midluteal CL. Immunohistochemistry revealed that StAR staining was most prominent in thecal-lutein cells throughout the luteal phase. The intensity of the signal for StAR exhibited significant changes throughout the luteal phase, being most intense during the midluteal phase and least during the late luteal phase. Plasma progesterone concentrations were highly correlated (r = 0.73 and r = 0.79) with luteal expression of the preprotein and mature StAR isoforms, respectively, throughout the luteal phase. To examine the LH dependency of StAR expression, the GnRH antagonist, Cetrorelix, was administered during the midluteal phase. Cetrorelix caused a decline in serum LH levels within 2 h, which, in turn, caused a pronounced decline in plasma progesterone within 6 h. The StAR 4.4-kb transcript was not detectable, and the 1.6-kb transcript was reduced by approximately 50% within 24 h of Cetrorelix treatment. The mature 30-kDa StAR protein level declined approximately 30% after Cetrorelix treatment. We conclude that 1) StAR mRNA and protein are highly expressed in early and midluteal phase CL; 2) StAR protein is present in both thecal-lutein and granulosa-lutein cells throughout the luteal phase; 3) StAR protein levels in the CL are highly correlated with plasma progesterone levels; 4) declining StAR mRNA and protein levels are characteristic of late luteal phase CL; and 5) suppression of LH levels during the midluteal phase results in a marked decline in plasma progesterone and a diminished abundance of StAR transcripts in the CL without a corresponding significant decline in StAR protein. Collectively, these data are consistent with the idea that StAR gene expression is a key determinant of luteal progesterone during the normal menstrual cycle. However, the pharmacologically induced withdrawal in the midluteal phase of LH support diminishes luteal progesterone output by mechanisms others than reduced StAR protein levels.
This article has been cited by other articles:
![]() |
P. R. Manna, M. T. Dyson, and D. M. Stocco Regulation of the steroidogenic acute regulatory protein gene expression: present and future perspectives Mol. Hum. Reprod., June 1, 2009; 15(6): 321 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Bishop, J. D. Hennebold, and R. L. Stouffer The effects of luteinizing hormone ablation/replacement versus steroid ablation/replacement on gene expression in the primate corpus luteum Mol. Hum. Reprod., March 1, 2009; 15(3): 181 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Y. Jarvela, A. Ruokonen, and A. Tekay Effect of rising hCG levels on the human corpus luteum during early pregnancy Hum. Reprod., December 1, 2008; 23(12): 2775 - 2781. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.D. Alvarez, A. Hansen, T. Ord, P. Bebas, P. E. Chappell, J. M. Giebultowicz, C. Williams, S. Moss, and A. Sehgal The Circadian Clock Protein BMAL1 Is Necessary for Fertility and Proper Testosterone Production in Mice J Biol Rhythms, February 1, 2008; 23(1): 26 - 36. [Abstract] [PDF] |
||||
![]() |
F. Del Canto, W. Sierralta, P. Kohen, A. Munoz, J. F. Strauss III, and L. Devoto Features of Natural and Gonadotropin-Releasing Hormone Antagonist-Induced Corpus Luteum Regression and Effects of in Vivo Human Chorionic Gonadotropin J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4436 - 4443. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Orozco, Z. Sosa, V. Fillipa, F. Mohamed, and A. M. Rastrilla The cholinergic influence on the mesenteric ganglion affects the liberation of ovarian steroids and nitric oxide in oestrus day rats: characterization of an ex vivo system J. Endocrinol., December 1, 2006; 191(3): 587 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Assou, T. Anahory, V. Pantesco, T. Le Carrour, F. Pellestor, B. Klein, L. Reyftmann, H. Dechaud, J. De Vos, and S. Hamamah The human cumulus-oocyte complex gene-expression profile Hum. Reprod., July 1, 2006; 21(7): 1705 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kohen, O. Castro, A. Palomino, A. Munoz, L. K. Christenson, W. Sierralta, P. Carvallo, J. F. Strauss III, and L. Devoto The Steroidogenic Response and Corpus Luteum Expression of the Steroidogenic Acute Regulatory Protein after Human Chorionic Gonadotropin Administration at Different Times in the Human Luteal Phase J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3421 - 3430. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Yadav, R. R. Sudhagar, and R. Medhamurthy Apoptosis During Spontaneous and Prostaglandin F2{alpha}-Induced Luteal Regression in the Buffalo Cow (Bubalus bubalis): Involvementof Mitogen-Activated Protein Kinases Biol Reprod, September 1, 2002; 67(3): 752 - 759. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |